Cyclophosphamide (CP) is widely used, alone or in combination with other chemotherapeutic agents, for treatment of neoplastic diseases. Its urotoxicity may cause dose-limiting side-effects, for example hemorrhagic cystitis. The agent most often used to prevent this side-effect is mesna (2-mercaptoethane sulfonate). Overproduction of reactive oxygen species during inflammation is one reason for possible urothelial injury. The aim of this study was to evaluate whether combinations of quercetin and epigallocatechin 3-gallate (EGCG), flavonoid antioxidants and mesna could prevent cystitis induced by cyclophosphamide, better than mesna alone. A total of 38 male Sprague-Dawley rats were divided into five groups. Four groups received single dose of CP (100 mg kg(-1)) intraperitoneally at the same time. Group 2 received CP only, group 3 received mesna (3 x 21.5 mg kg(-1)), group 4 received a single dose of mesna+EGCG (2 x 20 mg kg(-1)), and group 5 received a single dose of mesna+quercetin (2 x 20 mg kg(-1)), before and after CP injection. Group 1 (not treated) served as control. CP injection alone resulted in severe cystitis. Mesna resulted in some, but not full, protection against CP toxicity. Quercetin and catechine, together with mesna, resulted in full protection against CP toxicity, on the basis of histopathology of the urinary bladder. It was concluded that oxidants might be important in the pathogenesis of CP-induced cystitis, and that flavonoid antioxidants, used in addition to mesna, may help to ameliorate bladder damage.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00204-005-0647-7 | DOI Listing |
Sociol Health Illn
February 2025
Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Oxford, UK.
Fibromyalgia is a syndrome characterised by persistent unexplained pain and fatigue. People with fibromyalgia report receiving little support to manage symptoms, difficult interactions with healthcare practitioners and stigma associated with this contested condition. In this article, we employ Dorothy E Smith's Sociology for People to undertake a systems-focused literature review from the standpoint of people with fibromyalgia, moving beyond individual subjectivities to map how problems are socially organised.
View Article and Find Full Text PDFBlood Adv
February 2025
Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA.
Little is known about the impact of recent advances in acute myeloid leukemia (AML) treatment on racial/ethnic disparities in survival outcomes. We performed a retrospective cohort study of patients with newly diagnosed AML using data from a nationwide electronic health record-derived deidentified database. Patients were categorized based on their diagnosis date relative to venetoclax approval, as pre-novel therapy era (Pre era; 2014-2018; n = 2998) or post-novel therapy era (Post era; 2019-2022; n = 2098).
View Article and Find Full Text PDFIndian J Pediatr
January 2025
Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Objectives: To compare six doses of intrapleural streptokinase (SK) vs. the conventional three doses in children with empyema.
Methods: In this randomized controlled trial, children with empyema received intrapleural streptokinase, either twice daily for 3 d (total 6 doses); or once daily for 3 d (total 3 doses).
Eur Arch Paediatr Dent
January 2025
Faculty of Dentistry, Ain Shams University, Cairo, Egypt.
Purpose: The purpose of this study is to evaluate the influence of photobiomodulation therapy on the regenerative potential of non-vital mature permanent teeth of healthy Canine dogs.
Methods: 54 mature roots, obtained from 27 premolars, in dogs, were selected and divided into three equal groups where Group I received regenerative endodontic procedures (REPs) using blood clot as a scaffold (positive control), Group II received similar treatment as Group I, followed by photobiomodulation therapy (study group) and Group III did not receive any intervention (negative control). Each group was further divided into three equal subgroups for the evaluation of the vascular area percentage and fibroblast count at 3 different intervals; 3, 10, and 15 weeks.
J Endocrinol Invest
January 2025
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Via Rita Levi Montalcini 4, Milan, Italy.
Purpose: The real-world effectiveness of switching from denosumab to romosozumab remains controversial. Sequential therapy with romosozumab was shown to be associated with inadequate suppression of bone resorption and there was anecdotal evidence of major osteoporotic fractures (MOFs) after transitioning from denosumab to romosozumab. This study evaluated the effects on bone resorption of early romosozumab administration 3 months after denosumab withdrawal in fractured women with post-menopausal osteoporosis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!